Histamine H2 receptor desensitization in HL-60 human promyelocytic leukemia cells
- PMID: 6208354
Histamine H2 receptor desensitization in HL-60 human promyelocytic leukemia cells
Abstract
Recent studies have suggested that cyclic AMP (cAMP) may be involved in regulation of cell growth and differentiation of cancer cells. Incubating HL-60 cells in the presence of the specific H2 agonist dimaprit resulted in 30-fold increases in cAMP levels (EC50 = 5.7 X 10(-6) M) and morphological changes suggestive of cell maturation along the granulocyte pathway. However, cells cultured with 10(-5) M dimaprit showed more than an 80% decrease in their cAMP response to subsequent addition of H2 agonists, whereas the cAMP response to prostaglandin E2 was unaltered. Desensitization was time-dependent (halftime approximately 2.5 hr with 10(-5) M dimaprit), dose-dependent (dimaprit EC50 = 1.4 X 10(-6) M) and completely prevented by 10(-3) M cimetidine. Desensitization of HL-60 cells for 4 hr with 10(-5) M dimaprit followed by the addition of 10(-3) M cimetidine resulted in total recovery of the cAMP response in less than 24 hr. The pharmacologically inactive analog N-methyldimaprit (SK&F 92054) did not increase cAMP production or cause desensitization to H2 stimulation. Desensitization was observed in the presence or absence of a phosphodiesterase inhibitor, indicating that induction of cAMP-phosphodiesterase was not involved in this process. No difference in the number of [3H]tiotidine binding sites was observed between control and dimaprit-desensitized HL-60 cells. Based on these results, we suggest that H2 receptor agonists caused an agonist-dependent desensitization, presumably due to an uncoupling of receptors from adenylate cyclase.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Histamine modulates contraction and cyclic nucleotides in cultured rat mesangial cells. Differential effects mediated by histamine H1 and H2 receptors.J Clin Invest. 1985 May;75(5):1679-89. doi: 10.1172/JCI111876. J Clin Invest. 1985. PMID: 2582001 Free PMC article.
-
Identification and characterization of surface receptors for histamine in the human promyelocytic leukemia cell line HL-60. Comparison with human peripheral neutrophils.Mol Pharmacol. 1982 Nov;22(3):547-53. Mol Pharmacol. 1982. PMID: 6185835
-
Histamine increases cytosolic Ca2+ in HL-60 promyelocytes predominantly via H2 receptors with an unique agonist/antagonist profile and induces functional differentiation.Mol Pharmacol. 1992 Aug;42(2):235-41. Mol Pharmacol. 1992. PMID: 1381044
-
Regulation by prostaglandin E2 and histamine of angiogenesis in inflammatory granulation tissue.Yakugaku Zasshi. 2003 May;123(5):295-303. doi: 10.1248/yakushi.123.295. Yakugaku Zasshi. 2003. PMID: 12772586 Review.
-
[Role of H2-histamine receptors in the immunological response].Przegl Dermatol. 1981 Sep-Dec;68(5-6):627-30. Przegl Dermatol. 1981. PMID: 6126916 Review. Polish. No abstract available.
Cited by
-
Flow cytometric analysis with a fluorescently labeled formyl peptide receptor ligand as a new method to study the pharmacological profile of the histamine H2 receptor.Naunyn Schmiedebergs Arch Pharmacol. 2015 Oct;388(10):1039-52. doi: 10.1007/s00210-015-1133-2. Epub 2015 May 30. Naunyn Schmiedebergs Arch Pharmacol. 2015. PMID: 26021872
-
Stimulation of histamine H2- (and H1)-receptors activates Ca2+ influx in all-trans-retinoic acid-differentiated HL-60 cells independently of phospholipase C or adenylyl cyclase.Naunyn Schmiedebergs Arch Pharmacol. 1996 Jan;353(2):123-9. doi: 10.1007/BF00168748. Naunyn Schmiedebergs Arch Pharmacol. 1996. PMID: 8717151
-
Molecular and cellular analysis of human histamine receptor subtypes.Trends Pharmacol Sci. 2013 Jan;34(1):33-58. doi: 10.1016/j.tips.2012.11.001. Epub 2012 Dec 17. Trends Pharmacol Sci. 2013. PMID: 23254267 Free PMC article. Review.
-
The growth capacity of hematopoietic progenitor cells in severe neutropenia induced by famotidine.Ann Hematol. 1992 May;64(5):231-9. doi: 10.1007/BF01738302. Ann Hematol. 1992. PMID: 1623058
-
A novel network pharmacology approach for leukaemia differentiation therapy using Mogrify®.Oncogene. 2022 Nov;41(48):5160-5175. doi: 10.1038/s41388-022-02505-5. Epub 2022 Oct 21. Oncogene. 2022. PMID: 36271030
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical